Recruitment Status

Recruiting clinical trials

Status pages show live ClinicalTrials.gov search results by recruitment status, with direct links to official study records plus page-level filtering and sorting.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 7:44 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

21991

Shown on this page

Current sort

Live official records

Open in full search

Conditions: Depression, Major Depressive Disorder, Major Depression
Interventions: Arm 1, 2, 3 device interventions, Arm 2 Interventions, Arm 1, 2, 3 drug Interventions, Arm 1 and 2 Interventions; Device · Other · Drug
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Multiple Myeloma (MM)
Interventions: Cemsidomide, Elranatamab; Drug · Biological
Lead sponsor: C4 Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 19
States / cities: Gilbert, Arizona • Sacramento, California • Santa Monica, California + 16 more

Conditions: CRC (Colorectal Cancer)
Interventions: INCA33890, Placebo, Bevacizumab, FOLFOX; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 700 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 78
States / cities: Mobile, Alabama • Tucson, Arizona • Fountain Valley, California + 65 more

Conditions: Acute Promyelocytic Leukemia (APL), Acute Promyelocytic Leukaemia, Acute Promyelocytic Leukemia With PML-RARA, Acute Promyelocytic Leukemia With t(15;17)(q24.1;q21.2); PML-RARA, Acute Promyelocytic Leukemia
Interventions: QTX-2101 + ATRA, IV arsenic trioxide (ATO) + ATRA; Drug
Lead sponsor: Quetzal Therapeutics; Industry
Eligibility: 18 Years to 71 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 18
States / cities: Birmingham, Alabama • Duarte, California • Irvine, California + 14 more

Conditions: Advanced Solid Tumors
Interventions: GenSci143 for injection; Drug
Lead sponsor: Changchun GeneScience Pharmaceutical Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 4
States / cities: Los Angeles, California • Huntersville, North Carolina • Oklahoma City, Oklahoma + 1 more

Conditions: Facet Joint Arthropathy, Pain, Osteoarthritis
Interventions: Spinal angiography and embolization/ Embozene Microspheres; Device
Lead sponsor: Northwell Health; Other
Eligibility: 18 Years to 85 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Manhasset, New York

Conditions: Asthma
Interventions: Tozorakimab, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 540 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 65
States / cities: Bakersfield, California • Huntington Beach, California • La Mesa, California + 61 more

Conditions: Immune Thrombocytopenia
Interventions: INCA000585; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 9
States / cities: Glendale, Arizona • Los Angeles, California • Lone Tree, Colorado + 6 more

Conditions: Type 2 Diabetes Mellitus
Interventions: Elecoglipron, Dapagliflozin, Elecoglipron-matched placebo, Dapagliflozin-matched placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 2,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 45
States / cities: Huntsville, Alabama • Mobile, Alabama • Sheffield, Alabama + 41 more

Conditions: Trauma, Hemorrhage
Interventions: Calcium Gluconate, Vasopressin, saline placebo; Drug
Lead sponsor: Jason Sperry; Other
Eligibility: 18 Years to 90 Years
Enrollment: 1,050 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 18
States / cities: Chandler, Arizona • Tucson, Arizona • Little Rock, Arkansas + 13 more

Conditions: Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma, HR+ / HER2- Advanced Breast Cancer
Interventions: Ivermectin, Balstilmab, Pembrolizumab; Drug
Lead sponsor: Yuan Yuan; Other
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Asthma
Interventions: tilrekimig, Placebo; Drug · Other
Lead sponsor: Pfizer; Industry
Eligibility: 12 Years to 80 Years
Enrollment: 1,100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 13
States / cities: Bakersfield, California • Miami, Florida • White Marsh, Maryland + 10 more

Recruiting clinical trials

Filter and sort this status page

Live official records

Mechanism of Action Underlying Ketamine's Antidepressant Effects: The AMPA Throughput Theory in Patients With Treatment-Resistant Major Depression

A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects

A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia

GenSci143 in Participants With Advanced Solid Tumors

Trans-arterial Embolization for the Treatment of Facet Pain Due to Facet Arthropathy

Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adults With Uncontrolled Asthma on Medium-to-High Dose Inhaled Corticosteroids

Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Disorders

A Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes Mellitus

CAlcium and VAsopressin Following Injury Early Resuscitation (CAVALIER) Trial

Ivermectin in Combination With Balstilimab or Pembrolizumab in Patients With Metastatic Triple Negative Breast Cancer and HR+/HER2- Metastatic Breast Cancer

A Study to Learn About the Study Medicine Called Tilrekimig in People With Severe Asthma